Iteos Therapeutics Inc Total Liabilities
Iteos Therapeutics Inc total liabilities. Based on the latest financial reports, Iteos Therapeutics Inc (ITOS) has total liabilities worth $129.28 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ITOS asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Iteos Therapeutics Inc (2018–2024)
Total liabilities of Iteos Therapeutics Inc from 2018 to 2024. This chart illustrates how Iteos Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Iteos Therapeutics Inc to see how much of total assets are deployed in long-term investments.
Iteos Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Iteos Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen Haoningda Meters Co Ltd
SHE:002356
|
China | CN¥63.42 Million |
|
Bumble Inc
NASDAQ:BMBL
|
USA | $603.61 Million |
|
Vinci Partners Investments Ltd
NASDAQ:VINP
|
USA | $1.94 Billion |
|
PTC India Limited
NSE:PTC
|
India | Rs55.72 Billion |
|
CNFC Overseas Fishery Co Ltd
SHE:000798
|
China | CN¥4.31 Billion |
|
Shandong Teamgene Technology Co. Ltd. A
SHG:603151
|
China | CN¥2.46 Billion |
|
Heren Health Co Ltd
SHE:300550
|
China | CN¥268.81 Million |
|
Tengda Construction Group Co Ltd
SHG:600512
|
China | CN¥4.50 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Iteos Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ITOS total assets.
Liquidity & Leverage Metrics
Iteos Therapeutics Inc Total Liabilities Ratios Explained
Iteos Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Iteos Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Iteos Therapeutics Inc (2018–2024)
The table below shows the annual total liabilities of Iteos Therapeutics Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $96.68 Million | +4.68% |
| 2023-12-31 | $92.36 Million | +0.76% |
| 2022-12-31 | $91.66 Million | -72.38% |
| 2021-12-31 | $331.89 Million | +1453.73% |
| 2020-12-31 | $21.36 Million | +41.70% |
| 2019-12-31 | $15.07 Million | +22.18% |
| 2018-12-31 | $12.34 Million | -- |
About Iteos Therapeutics Inc
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lym… Read more